Prospects for Improving Brain Function in Individuals with Down Syndrome - Wikidata - wikimedia - TriplyDB

Prospects for Improving Brain Function in Individuals with Down Syndrome

Prospects for Improving Brain Function in Individuals with Down Syndrome

http://www.wikidata.org/entity/Q22252566

about

Timing of therapies for Down syndrome: the sooner, the better Regulation of emotional response in juvenile monkeys treated with fluoxetine: MAOA interactions Sleep disturbance as detected by actigraphy in pre-pubertal juvenile monkeys receiving therapeutic doses of fluoxetine Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives.Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome.Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.DS-Connect: A Promising Tool to Improve Lives and Engage Down Syndrome Communities Worldwide Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.Integrated care for Down syndrome.Generation of Integration-Free Induced Pluripotent Stem Cells from Urine-Derived Cells Isolated from Individuals with Down Syndrome.A quantitative transcriptome reference map of the normal human brain.Developmental excitatory-to-inhibitory GABA-polarity switch is disrupted in 22q11.2 deletion syndrome: a potential target for clinical therapeutics.Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome?Infantile spasms in down syndrome: Rescue by knockdown of the GIRK2 channel.Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.Three-Dimensional Hyaluronic Acid Hydrogel-Based Models for In Vitro Human iPSC-Derived NPC Culture and Differentiation.Intracellular chloride accumulation: a possible mechanism for cognitive deficits in Down syndrome.Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date.Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.

P2860

Q26779297-186CD89F-40EB-4DCD-B6DA-C66244618AF6 Q28396360-54DEDA82-B537-4D52-84F6-E1A94ED99973 Q30762930-A4F7B97C-B8FA-4A4D-91EB-69771FA6F5D4 Q33659830-B0F64349-E24A-4E96-8A39-2AA79B40E5DB Q33711022-95F3F8DC-5824-435F-8139-5E91D953C812 Q35733743-F3DFB7CD-BC26-4552-8C5F-BA843B53F973 Q36405007-A7C04627-E515-423A-9C62-2D501F4BB80F Q36621106-6F07AB2D-0095-48DC-903D-46277A3A2BEC Q37279515-F9480A97-18E1-461C-8799-6EDB82451E65 Q38729246-75020A68-E592-4B8C-B243-3B0EE3DD146B Q38735784-155502A1-0D40-4F5E-BBAA-57A0E85AF5FF Q44829074-8A0E8530-4649-4D3C-9C7E-E039D4CF6D0E Q45738093-201DD9A0-7756-42AE-AF85-69F8F6FC7608 Q46417261-40EE60DA-201A-4FC9-8BDB-987A53AA0430 Q47972710-C027B9F4-D8CF-4ED0-81EC-FA8086CA31D5 Q50202346-C1180F99-85B0-4547-9C02-661A153A6807 Q50431066-A20A9CD4-0B14-447F-8F70-576EBDBE7BEB Q50592864-EDF187FE-E7EF-4692-BEA6-1023A1289233 Q53081143-DECC23FE-7336-4EBE-A7DA-96A3AC9418CD Q55313635-2D5EBB6E-479C-4750-8C7D-2EC1EECB7E14

P2860

Prospects for Improving Brain Function in Individuals with Down Syndrome

http://www.wikidata.org/entity/Q22252566

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Prospects for Improving Brain Function in Individuals with Down Syndrome

@ast

Prospects for Improving Brain Function in Individuals with Down Syndrome

@en

Prospects for Improving Brain Function in Individuals with Down Syndrome

@nl

type

label

Prospects for Improving Brain Function in Individuals with Down Syndrome

@ast

Prospects for Improving Brain Function in Individuals with Down Syndrome

@en

Prospects for Improving Brain Function in Individuals with Down Syndrome

@nl

altLabel

Prospects for improving brain function in individuals with Down syndrome

@en

prefLabel

Prospects for Improving Brain Function in Individuals with Down Syndrome

@ast

Prospects for Improving Brain Function in Individuals with Down Syndrome

@en

Prospects for Improving Brain Function in Individuals with Down Syndrome

@nl

P1433

Q22252566-98655FE9-3C43-4901-BFD2-395C5030B2A7

P1476

Q22252566-F3994AB0-D30B-4F1E-84DE-EF96CC8F12B4

P2093

Q22252566-25F49F62-95EA-4D3A-B39D-6E64842F5721

Q22252566-7B0FFF63-A50A-45F3-9DBD-F92CA1A5D11B

P2860

Q22252566-02854886-E330-4468-9CF3-3DE4FBA2EE43

Q22252566-039D7B45-7234-4D16-B67D-D9D67549C67C

Q22252566-08A0C00C-1B67-4DD9-98AF-94265F3E4ADE

Q22252566-091DC1EB-FC07-4C15-8DB3-73E8EF44A9D7

Q22252566-0BDDF40F-0939-4FED-83B0-219D468F0449

Q22252566-0D3A1BDC-F394-4301-8429-F45727500776

Q22252566-0D88930E-27B7-450B-9558-CA87D1188283

Q22252566-114EA9CC-37DF-470D-BB9B-C593189CC15D

Q22252566-1337DAEC-1F23-47F1-8174-D3BC746AB82F

Q22252566-140B5F08-E7FF-4E56-B627-D50706A2A0B5

P2888

Q22252566-FBDE9219-5A38-4E3A-A7C5-B591599D462D

P304

Q22252566-3282367D-8011-4E57-840E-090113CA5E11

P31

Q22252566-B664FC51-029B-478A-BCD1-1591E9BBB957

P356

Q22252566-A14EEC01-5ED4-4C55-BD96-7BE2B812B7D1

P407

Q22252566-514CC1F6-6158-4C03-A688-BAB1AA01E190

P433

Q22252566-1F655578-71B2-486E-9312-3F7448622855

P478

Q22252566-09B231C1-FFC3-45BA-9BFB-55F13ECEB413

P50

Q22252566-B2CB1E7E-86F4-4982-B88F-FD6E5D4609ED

Q22252566-DAC960CF-F006-4E63-8667-8AA3D15F6228

P577

Q22252566-96A59785-7C3D-4309-9B3B-B99793C6A8B3

P5875

Q22252566-B863EA9F-B3E0-4741-8CEA-FC25CF1B6795

P6179

Q22252566-F67D67A8-6316-4911-9795-415BF4531F85

P698

Q22252566-46F2B9C8-9AFB-4871-B328-C963CBF637E7

P921

Q22252566-0AD08415-7AF5-4C87-A92B-B9B44B8630E8

P356

S40263-013-0089-3

P1433

P1476

Prospects for improving brain function in individuals with Down syndrome

@en

P2093

Alberto C. S. Costa

http://www.w3.org/2001/XMLSchema#string

Jonah J. Scott-McKean

http://www.w3.org/2001/XMLSchema#string

P2860

DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase

Can animal models of disease reliably inform human studies?

Initial sequencing and comparative analysis of the mouse genome

On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome

Role of numb in dendritic spine development with a Cdc42 GEF intersectin and EphB2.

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial

Supplementation with antioxidants and folinic acid for children with Down's syndrome: randomised controlled trial

Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia

The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21

The Rac1-GEF Tiam1 couples the NMDA receptor to the activity-dependent development of dendritic arbors and spines

P2888

s40263-013-0089-3

P304

679-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40263-013-0089-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Jonah J Scott-McKean

Alberto C Costa

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244992006

http://www.w3.org/2001/XMLSchema#string

P6179

1038649250

http://www.w3.org/2001/XMLSchema#string

P698

23821040

http://www.w3.org/2001/XMLSchema#string

P921